S&P 500 7557.81 +0.19%
NASDAQ 26227.12 +0.08%
TASI 10808.43 -0.42%
Oil (WTI) 71.45 -0.87%
Oil (Brent) 75.95 -0.46%
VIX 15.45 -2.46%
Gold 4110.80 -0.72%
USD/SAR 3.75 +0.01%

Regeneron Pharmaceuticals, Inc.

REGN · Healthcare · · USD
661.85 USD
0.00 (-0.91%)
● Updated 2026-07-10 19:08 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Long-term (Investment)

67
/ 100
Technical 50
Trend & RS 63
Momentum 40
Fundamental 89
Macro 71
Liquidity 38
ComponentScoreWeight
Technical 50.0 10%
Trend & RS 63.1 10%
Momentum 40.3 5%
Fundamental 88.9 40%
Macro 71.2 15%
Liquidity 38.4 20%

Trade Setup

Entry 662.67
Stop Loss 629.41 (5.0%)
Target 1 (1:1) 695.93 (+5.0%)
Target 2 (2:1) 729.19 (+10.0%)
ATR(14) 16.63 (2.5%)
Risk per Share 33.26
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 71.5 +0.86
Momentum 40.3 -0.39
Quality 72.0 +0.88
Composite 61.3

Quality Scores

Piotroski F-Score 7 /9 — Strong
✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 17.69 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio 16.2 22.0 -26% below
P/B Ratio 2.1 4.0 Below
Dividend Yield 56.0% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Intrinsic Value (DCF) Significantly Undervalued

Intrinsic Value
1016.02
vs
Market Price
661.85
Upside
+53.5%
Margin of Safety +34.9%
Stage 1 PV (5yr FCF)22,128,157,928
Terminal Value PV82,544,133,941
Total Enterprise Value104,672,291,869

Assumptions

Base FCF3,374,996,985
Growth Rate (5yr)19.0%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
44.03%
Full Kelly
22.02%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 67/100. Estimated win rate 60%, avg win 9.0%, avg loss 3.7%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary BUY

2
Bullish Signals
2
Bearish Signals
58.48
RSI(14)
6.138
MACD

Relative Strength (RS) NEUTRAL

82
/ 99
RS Rating
✓ O'Neil PASS (≥80)
RS vs SPY → FLAT (-24.6% vs SPY 3M)
RS vs Sector UNDERPERFORMING (Healthcare)
RS New High No (62d since high)
Sector Outperformance -16.7% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
NEUTRAL: In line with the market — no strong outperformance or underperformance.

Technical Indicators

IndicatorValueSignal
Rsi 58.48 NEUTRAL
Macd 6.138 BULLISH
Ma Cross 648.81 / 700.28 DEATH CROSS
Trend Short ABOVE SMA50
Trend Long BELOW SMA200
Bollinger MIDDLE
Volume 0.16x LOW

Key Levels

LevelPrice
52-Week High821.11
Bollinger Upper675.94
SMA(200)700.28
SMA(50)648.81
SMA(20)631.6
Current Price661.85
Bollinger Lower587.27
52-Week Low541.00
ATR(14)16.63

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKDOWN Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 0.0  |  Markdown: 2.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-06 Normal 0.71x Normal bar — no special VSA pattern
2026-07-07 Normal 0.92x Normal bar — no special VSA pattern
2026-07-08 Normal 0.75x Normal bar — no special VSA pattern
2026-07-09 Normal 0.67x Normal bar — no special VSA pattern
2026-07-10 Normal 0.16x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 650.11 Above Kijun
Kijun-sen (26) 636.41 Base line
Senkou A 643.26 Leading span A
Senkou B 673.40 Leading span B
Cloud 643.26 – 673.40 Bearish (Red)
Price vs Cloud 662.67 Inside Cloud
Chikou Span 618.95 Bullish
Alignment Score 2/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 587.27 – 675.94  |  KC: 608.59 – 654.62

Divergences (last 60 bars)

No significant divergences detected in the last 60 bars.

Anchored VWAP

VWAP: 664.28 Anchor: 2025-07-18 (52w Low) BELOW AVWAP -0.2%

Heikin-Ashi Trend

BULLISH Full data via /api/advanced/REGN

Valuation

MetricValue
Market Cap69.39B
P/E (TTM)16.16
Forward P/EN/A
P/B2.15
EPS40.95

Financial Health

MetricValue
Revenue Growth19.0%
Profit Margin29.6%
ROE14.5%
Debt/Equity8.61
Current Ratio3.56
Dividend Yield56.0%
Payout RatioN/A
Beta0.24

Trading Data

661.85
Open
661.85
Day High
661.85
Day Low
159.7K
Volume (0.2x avg)

Recent News (8)

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
MT Newswires · 2026-07-08
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?
Insider Monkey · 2026-07-08
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside
Trefis · 2026-07-08
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
24/7 Wall St. · 2026-07-07
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Zacks · 2026-07-07
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Zacks · 2026-07-06
Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran
Simply Wall St. · 2026-07-04
Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain
Simply Wall St. · 2026-07-04

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —